Cargando…
Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
The HER2/neu (ERBB2) oncogene is amplified and/or overexpressed in approximately 20% of breast cancers, and is a strong prognostic factor for relapse and poor overall survival, particularly in node-positive patients. It is also an important predictor for response to trastuzumab, which has establishe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829743/ https://www.ncbi.nlm.nih.gov/pubmed/27095932 http://dx.doi.org/10.5114/wo.2016.58495 |